Reports Q4 revenue $22.418M, consensus $20.82M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
- Optinose downgraded to Neutral from Buy at H.C. Wainwright
- Optinose downgraded to Neutral from Overweight at Piper Sandler
- Hold Rating Issued Amid Optinose Acquisition by Paratek Pharmaceuticals with Adjusted Price Target
- Optinose downgraded to Hold from Buy at Lake Street
- Paratek Pharmaceuticals to acquire Optinose in $330M transaction